Schroder Investment Management Group Sells 180,941 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Schroder Investment Management Group reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 19.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 743,230 shares of the biopharmaceutical company's stock after selling 180,941 shares during the period. Schroder Investment Management Group owned 0.70% of Intra-Cellular Therapies worth $62,045,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. M&T Bank Corp increased its position in shares of Intra-Cellular Therapies by 2.2% during the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company's stock worth $526,000 after acquiring an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock valued at $748,000 after buying an additional 141 shares during the last quarter. CIBC Asset Management Inc boosted its stake in shares of Intra-Cellular Therapies by 5.3% during the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company's stock worth $247,000 after buying an additional 150 shares during the period. Pallas Capital Advisors LLC raised its stake in shares of Intra-Cellular Therapies by 6.4% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock worth $266,000 after purchasing an additional 192 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Intra-Cellular Therapies by 0.8% in the fourth quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company's stock valued at $2,302,000 after acquiring an additional 206 shares in the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Finally, StockNews.com began coverage on shares of Intra-Cellular Therapies in a research note on Friday, March 28th. They set a "hold" rating on the stock. Eleven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies has an average rating of "Hold" and a consensus price target of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI remained flat at $131.87 during trading on Friday. The business's fifty day moving average is $129.53 and its 200 day moving average is $101.03. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The stock has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.